353 related articles for article (PubMed ID: 12549768)
1. Chemoprevention of prostate cancer: current status and future directions.
Lieberman R
Cancer Metastasis Rev; 2002; 21(3-4):297-309. PubMed ID: 12549768
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
4. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
5. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.
Nelson WG; Wilding G
Urology; 2001 Apr; 57(4 Suppl 1):56-63. PubMed ID: 11295596
[TBL] [Abstract][Full Text] [Related]
8. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
9. Is There a Future for Chemoprevention of Prostate Cancer?
Bosland MC
Cancer Prev Res (Phila); 2016 Aug; 9(8):642-7. PubMed ID: 27099271
[TBL] [Abstract][Full Text] [Related]
10. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
Fujimoto N; Chang C; Nomura M; Matsumoto T
Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of prostate cancer.
Kucuk O
Cancer Metastasis Rev; 2002; 21(2):111-24. PubMed ID: 12465750
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators for the chemoprevention of prostate cancer.
Steiner MS; Raghow S; Neubauer BL
Urology; 2001 Apr; 57(4 Suppl 1):68-72. PubMed ID: 11295598
[TBL] [Abstract][Full Text] [Related]
13. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Fabian CJ; Kimler BF
Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention for prostatic intraepithelial neoplasia.
Nelson PS; Gleason TP; Brawer MK
Eur Urol; 1996; 30(2):269-78. PubMed ID: 8875211
[TBL] [Abstract][Full Text] [Related]
15. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Parnes HL; House MG; Kagan J; Kausal DJ; Lieberman R
J Urol; 2004 Feb; 171(2 Pt 2):S68-74; discussion S75. PubMed ID: 14713758
[TBL] [Abstract][Full Text] [Related]
18. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of prostate cancer: concepts and strategies.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.
Steiner MS; Raghow S
World J Urol; 2003 May; 21(1):31-6. PubMed ID: 12756492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
